We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI (TASQ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03186339
Recruitment Status : Completed
First Posted : June 14, 2017
Last Update Posted : May 18, 2022
Sponsor:
Collaborator:
Edwards Lifesciences
Information provided by (Responsible Party):
Institut für Pharmakologie und Präventive Medizin

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Prospective, multi-centre, multi-national registry with a follow-up of 3 months, in five European countries and Canada (Toronto), with elective patients undergoing TF-TAVI (n=120) and isolated SAVR (n=120), respectively and a control group of 50 patients receiving medical treatment only. All patient groups will fill in three different questionnaires to assess quality of life in 5 different languages (English, French, German, Italian and Spanish). One of these will be a new questionnaire, the Toronto Aortic Stenosis QoL (Quality of Life) questionnaire (TASQ).

Condition or disease Intervention/treatment
Aortic Valve Stenosis Procedure: TAVI Procedure: SAVR Other: MM

Detailed Description:

Currently, there are two cardiovascular disease QoL scales which have been used in studies of patients with aortic stenosis - the Minnesota Living with Heart Failure (MLHF) questionnaire and the Kansas City Cardiomyopathy Questionnaire (KCCQ).

The KCCQ has now become the only cited health related (HR) QoL validated scale for use among a growing TAVI (Transcatheter Aortic Valve Implantation) patient population; however questions on the KCCQ do not reflect the concerns and lifestyle of patients proceeding for aortic valve intervention. Many of the questions do not reflect this patient population's perspective of well-being in contrast to perceptions by the general cardiac population on which it was validated. It is important to capture the disruptions caused by a chronic disease and its treatment on lifestyles, activities, and interests; that is interference with psychologically meaningful activity. It has been noted that this interference varies by disease process and treatment by general scales such as the Illness Intrusiveness Scale .

Due to issues of limited validity of the KCCQ for TAVI / SAVR (Surgical Aortic Valve Replacement) patients related to symptom items not being revised from their original use for congestive heart failure, a new original HR-QoL questionnaire was proposed: The "Toronto Aortic Stenosis Quality of Life Questionnaire" (TASQ) is a health specific measurement tool designed to measure changes in quality of life in aortic stenosis patients. The aim of this study is to validate this questionnaire in this specific patient population.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 272 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Validation of the "Toronto Aortic Stenosis Quality of Life Questionnaire" in Patients Undergoing Surgical Aortic Valve Replacement or Transfemoral Transcatheter Aortic Valve Implantation The TASQ Registry
Actual Study Start Date : September 8, 2017
Actual Primary Completion Date : August 15, 2019
Actual Study Completion Date : January 13, 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
TAVI patients
patients undergoing TF (transfemoral) TAVI as treatment for the aortic stenosis
 Procedure: TAVI
transfemoral transcatheter aortic valve implantation
SAVR patients
patients undergoing isolated surgical valve replacement as treatment for the aortic stenosis
 Procedure: SAVR
isolated surgical valve replacement
MM patients
patients in whom the aortic stenosis is medically managed
 Other: MM
management of aortic stenosis by medical treatment only


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in QoL as assessed by SF12 (Short Form 12) Questionnaire [ Time Frame: 3 months from baseline examination ]
    Change in quality of life as assessed by the SF12 using a points system

  2. Change in QoL as assessed by KCCQ (The Kansas City Cardiomyopathy Questionnaire) [ Time Frame: 3 months from baseline examination ]
    Change in quality of life as assessed by the KCCQ using a points system

  3. Change in QoL as assessed by TASQ (Toronto Aortic Stenosis Quality of Life Questionnaire) [ Time Frame: 3 months from baseline examination ]
    Change in quality of life as assessed by the TASQ using a points system


Secondary Outcome Measures :
  1. Difference in change in QoL between arms [ Time Frame: 3 months from baseline examination ]
    Difference in change in QoL between the three intervention arms


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
120 consecutive patients undergoing TF-TAVI, 120 patients undergoing SAVR, and a control group of 50 patients receiving medical treatment will be enrolled. Because of an expected loss during follow-up with not all patients returning this will result in about 100 patients for both TAVI and SAVR and 40 for medical management or 48 per language.
Criteria

Inclusion Criteria:

  • severe aortic stenosis
  • age > 18 years
  • in case of TAVI or SAVR: intention to treat the AS employing an Edwards valve

Exclusion Criteria:

  • patients not providing informed consent
  • patients with major cognitive impairment
  • emergency patients
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03186339


Locations
Layout table for location information
Austria
Medical University of Innsbruck
Innsbruck, Austria, A-6020
Canada, Ontario
University Health Network, Toronto General Hospital
Toronto, Ontario, Canada, ON 5MG 2C4
France
Hospital Jacques Cartier
Massy, France, 91300
Bichat Hospital - Claude-Bernard
Paris, France, 75018
Germany
UKSH University Clinical Center Schleswig-Holstein
Kiel, Schleswig-Holstein, Germany, 24105
Italy
Structual Interventional Cardiology, University Hospital Careggi
Florence, Italy, 50134
Department of Medicine, University of Verona
Verona, Italy, 37126
Spain
University Hospital Vall d'Hebron
Barcelona, Spain, 08035
Hospital Juan Canalejo Coruna
Coruna, Spain, 15006
United Kingdom
Barts Heart Centre
London, United Kingdom, EC1A7BE
Sponsors and Collaborators
Institut für Pharmakologie und Präventive Medizin
Edwards Lifesciences
Investigators
Layout table for investigator information
Principal Investigator: Rima Styra, MD University Health Network, Toronto General Hospital, Ontario, Canada
Principal Investigator: Derk Frank, Prof. UKSH University Clinical Center Schleswig-Holstein, Germany
Principal Investigator: Simon Kennon, MD Barts Heart Centre, London, UK
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:

Other Publications:

Layout table for additonal information
Responsible Party: Institut für Pharmakologie und Präventive Medizin
ClinicalTrials.gov Identifier: NCT03186339    
Other Study ID Numbers: IPPM2017TASQ
First Posted: June 14, 2017    Key Record Dates
Last Update Posted: May 18, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut für Pharmakologie und Präventive Medizin:
QoL
TAVI
surgical aortic valve replacement
Aortic stenosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Aortic Valve Stenosis
Constriction, Pathologic
Pathological Conditions, Anatomical
Aortic Valve Disease
 Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Ventricular Outflow Obstruction